Other Events ·
Insmed Incorporated announced positive 12-month data from its ongoing open-label extension study of treprostinil…
INSMINSMED Inc
Insmed Incorporated announced positive 12-month data from its ongoing open-label extension study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). The data demonstrated sustained improvement across all secondary efficacy measures, including a reduction in mortality risk status by REVEAL Lite 2.0, and showed that patients who switched from placebo to TPIP achieved similar clinical benefits to those who continued TPIP. Insmed is a global biopharmaceutical company that develops therapies for serious diseases.